These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 685748)

  • 1. [Pharmacokinetic studies with mexiletine in patients with renal insufficiency].
    Herbinger W; Kramar R; Fridrik M; Häselbarth V; Pollmann WP
    Adv Clin Pharmacol; 1978; 16():17-27. PubMed ID: 685748
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of mexiletine in renal insufficiency.
    Baudinet G; Henrard L; Quinaux N; El Allaf D; de Landsheere C; Carlier J; Dresse A
    Acta Cardiol Suppl; 1980; (25):55-65. PubMed ID: 6966453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption, distribution and elimination of mexiletine.
    Prescott LF; Pottage A; Clements JA
    Postgrad Med J; 1977; 53 Suppl 1():50-5. PubMed ID: 876954
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics of mexiletine in renal insufficiency.
    El Allaf D; Henrard L; Crochelet L; Delapierre D; Carlier J; Dresse A
    Br J Clin Pharmacol; 1982 Sep; 14(3):431-5. PubMed ID: 7126416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of metoclopramide and atropine on the absorption of orally administered mexiletine.
    Wing LM; Meffin PJ; Grygiel JJ; Smith KJ; Birkett DJ
    Br J Clin Pharmacol; 1980 May; 9(5):505-9. PubMed ID: 6994791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of intravenous mexiletine in patients with acute myocardial infarction.
    Pentikäinen PJ; Halinen MO; Helin MJ
    J Cardiovasc Pharmacol; 1984; 6(1):1-6. PubMed ID: 6199590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variable pharmacokinetics of mexiletine.
    Kaye CM; Kiddie MA; Turner P
    Postgrad Med J; 1977; 53 Suppl 1():56-9. PubMed ID: 17856
    [No Abstract]   [Full Text] [Related]  

  • 8. [Kinetics of mexiletine distribution in the rat].
    Barrigón S; Tamargo J; García de Jalón PD
    Arch Farmacol Toxicol; 1983 Apr; 9(1):65-76. PubMed ID: 6625676
    [No Abstract]   [Full Text] [Related]  

  • 9. Adaptation of the dose of mexiletine according to pharmacokinetic data.
    Bogaert M
    Acta Cardiol Suppl; 1980; (25):67-73. PubMed ID: 6966454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of spontaneous changes in urinary pH on mexiletine plasma concentrations and excretion during chronic administration to healthy volunteers.
    Johnston A; Burgess CD; Warrington SJ; Wadsworth J; Hamer NA
    Br J Clin Pharmacol; 1979 Oct; 8(4):349-52. PubMed ID: 41549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption of mexiletine after treatment with gastric antacids.
    Herzog P; Holtermüller KH; Kasper W; Meinertz T; Trenk D; Jähnchen E
    Br J Clin Pharmacol; 1982 Nov; 14(5):746-7. PubMed ID: 7138757
    [No Abstract]   [Full Text] [Related]  

  • 12. Cirrhosis of the liver markedly impairs the elimination of mexiletine.
    Pentikäinen PJ; Hietakorpi S; Halinen MO; Lampinen LM
    Eur J Clin Pharmacol; 1986; 30(1):83-8. PubMed ID: 3709636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereoselective disposition of mexiletine in man.
    Grech-Belanger O; Turgeon J; Gilbert M
    Br J Clin Pharmacol; 1986 May; 21(5):481-7. PubMed ID: 3718807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical considerations in the treatment of ventricular arrhythmias with mexiletine.
    Akhtar M
    Am Heart J; 1984 May; 107(5 Pt 2):1086-90. PubMed ID: 6372424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mexiletine disposition: individual variation in response to urine acidification and alkalinisation.
    Mitchell BG; Clements JA; Pottage A; Prescott LF
    Br J Clin Pharmacol; 1983 Sep; 16(3):281-4. PubMed ID: 6626420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic parameters in patients treated with oral mexiletine.
    Vozeh S; Katz G; Steiner V; Follath F
    Eur J Clin Pharmacol; 1982; 23(5):445-51. PubMed ID: 7151850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between plasma levels, salivary concentrations and urinary excretion rates of mexiletene [proceedings].
    Beckett AH; Chidomere EC
    J Pharm Pharmacol; 1976 Dec; 28 Suppl():58P. PubMed ID: 12335
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction.
    Pentikäinen PJ; Halinen MO; Helin MJ
    Eur J Clin Pharmacol; 1983; 25(6):773-7. PubMed ID: 6662176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rifampicin treatment on the kinetics of mexiletine.
    Pentikäinen PJ; Koivula IH; Hiltunen HA
    Eur J Clin Pharmacol; 1982; 23(3):261-6. PubMed ID: 6129140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase of mexiletine plasma levels due to delayed hepatic metabolism in patients with chronic liver disease.
    Nitsch J; Steinbeck G; Lüderitz B
    Eur Heart J; 1983 Nov; 4(11):810-4. PubMed ID: 6653593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.